{"entity":{"id":"nct02966756","kind":"trial","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","aka":[],"tldr":"A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by AbbVie, active and no longer recruiting.","summary":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT02966756 by AbbVie, with 66 participants enrolled, started 2017-10-12 and due to reach its primary completion in 2030-12. Interventions recorded: Venetoclax.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02966756","url":"https://clinicaltrials.gov/study/NCT02966756"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["venetoclax"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02966756","phase":"2","setting":"A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sponsor":"AbbVie","enrolled":66,"outcomes":[]},"route":"/trials/nct02966756/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}